Clinical Features of Cellular Senescence Pathways in Severe Asthma
Woo‐Jung Song, Nazanin Zounemat Kermani, Ali Versi, Stephany Sánchez‐Ovando, Jodie Louise Simpson, Peter A. Wark, Katherine Joanne Baines, Sven‐Erik Dahlén, Ratko Djukanovic, Yike Guo, Ian M. Adcock, Kian Fan Chung,ABSTRACT
Background
Asthma severity increases with age, suggesting a role for accelerated biological ageing. We hypothesised that cellular senescence pathways such as the senescence‐associated secretory pathway (SASP) and the p53‐cellular senescence pathway are enriched in the airways of patients with severe asthma.
Methods
We utilised transcriptomic data from the U‐BIOPRED cohort to analyse enrichment scores (ES) of p53 and SASP pathways in different airway compartments using gene set variation analysis. Findings in bronchial biopsies were validated in the independent NOVA cohort. We examined associations between senescence ES, clinical parameters and other asthma‐related gene signatures. Functional clusters of the SASP gene set were also explored.
Results
In the U‐BIOPRED cohort, p53 and SASP ES were significantly elevated in bronchial biopsies of severe asthmatics compared to mild‐to‐moderate asthmatics and healthy volunteers, with SASP enrichment validated in the NOVA cohort. In bronchial biopsies, higher senescence ES correlated with frequent exacerbations, oral corticosteroid use, comorbid nasal polyps and lower FEV1%. No significant enrichment was found in other airway samples according to asthma severity. In nasal brushings, SASP ES was significantly higher in participants with comorbid nasal polyps. A distinct SASP functional cluster related to lung injury and repair (Cluster 2) was strongly associated with clinical severity and nasal polyps. Senescence signatures correlated positively with oxidative phosphorylation and macrophage activation signatures, but not with eosinophil signatures.
Conclusions
Cellular senescence pathways are enriched in severe asthmatic bronchial tissues and correlate with disease severity, remodelling and nasal polyps. These findings warrant further investigation into their therapeutic implications.
Trial Registration
NCT01982162